Source: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/adverse-events.html
Serious adverse events after COVID-19 vaccination are rare but may occur.
For public awareness and in the interest of transparency, CDC is providing timely updates on the following serious adverse events of interest:
- Anaphylaxis after COVID-19 vaccination is rare and has occurred in approximately 2 to 5 people per million vaccinated in the United States. Severe allergic reactions, including anaphylaxis, can occur after any vaccination. If this occurs, vaccination providers can effectively and immediately treat the reaction. Learn more about COVID-19 vaccines and allergic reactions, including anaphylaxis.
- Thrombosis with thrombocytopenia syndrome (TTS) after Johnson & Johnson’s Janssen (J&J/Janssen) COVID-19 vaccination is rare. As of October 27, 2021, more than 15.5 million doses of the J&J/Janssen COVID-19 Vaccine have been given in the United States. CDC and FDA identified 48 confirmed reports of people who got the J&J/Janssen COVID-19 Vaccine and later developed TTS. Women younger than 50 years old especially should be aware of the rare but increased risk of this adverse event. There are other COVID-19 vaccine options available for which this risk has not been seen. Learn more about J&J/Janssen COVID-19 Vaccine and TTS.
- To date, two confirmed cases of TTS following mRNA COVID-19 vaccination (Moderna) have been reported to VAERS after more than 401 million doses of mRNA COVID-19 vaccines administered in the United States. Based on available data, there is not an increased risk for TTS after mRNA COVID-19 vaccination.
- CDC and FDA are monitoring reports of Guillain-Barré Syndrome (GBS) in people who have received the J&J/Janssen COVID-19 Vaccine. GBS is a rare disorder where the body’s immune system damages nerve cells, causing muscle weakness and sometimes paralysis. Most people fully recover from GBS, but some have permanent nerve damage. After more than 15.5 million J&J/Janssen COVID-19 Vaccine doses administered, there have been around 244 preliminary reports of GBS identified in VAERS as of October 27, 2021. These cases have largely been reported about 2 weeks after vaccination and mostly in men, many 50 years and older. CDC will continue to monitor for and evaluate reports of GBS occurring after COVID-19 vaccination and will share more information as it becomes available.
- Myocarditis and pericarditis after COVID-19 vaccination are rare. As of October 27, 2021, VAERS has received 1,784 reports of myocarditis or pericarditis among people ages 30 and younger who received COVID-19 vaccine. Most cases have been reported after mRNA COVID-19 vaccination (Pfizer-BioNTech or Moderna), particularly in male adolescents and young adults. Through follow-up, including medical record reviews, CDC and FDA have confirmed 1,005 reports of myocarditis or pericarditis. CDC and its partners are investigating these reports to assess whether there is a relationship to COVID-19 vaccination. Learn more about COVID-19 vaccines and myocarditis.
- Reports of death after COVID-19 vaccination are rare. More than 423 million doses of COVID-19 vaccines were administered in the United States from December 14, 2020, through November 1, 2021. During this time, VAERS received 9,367 reports of death (0.0022%) among people who received a COVID-19 vaccine. FDA requires healthcare providers to report any death after COVID-19 vaccination to VAERS, even if it’s unclear whether the vaccine was the cause. Reports of adverse events to VAERS following vaccination, including deaths, do not necessarily mean that a vaccine caused a health problem. A review of available clinical information, including death certificates, autopsy, and medical records, has not established a causal link to COVID-19 vaccines. However, recent reports indicate a plausible causal relationship between the J&J/Janssen COVID-19 Vaccine and TTS, a rare and serious adverse event—blood clots with low platelets—which has caused deaths pdf icon[1.4 MB, 33 pages].
COVID-19 Vaccine Safety Updates
Advisory Committee on Immunization Practices (ACIP)
Oct 21, 2021
Tom Shimabukuro, MD, MPH, MBA
Vaccine Safety Team
CDC COVID-19 Vaccine Task Force
the news network 